Background and objective In patients with severe interstitial lung disease ( ILD ) progressing despite conventional immunosuppression, rituximab, a B ‐lymphocyte depleting monoclonal antibody, may offer an effective rescue therapy. Methods Retrospective assessment of 50 patients with severe, prog…